Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals ...Middle East

PR Newswire - News
STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement...

Hence then, the article about sprint bioscience licenses the cancer drug program vps34 to deciphera pharmaceuticals was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News